UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D

Clinical microbiology and infection, 2015-06, Vol.21 (6), p.606.e1-606.e10

2015

Volltextzugriff (PDF)

Alkalosis, albumin, ammonia and hepatic encephalopathy

Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2021-05, Vol.116 (4), p.358-359

2021

Volltextzugriff (PDF)

Editorial: retreatment of DAA‐failures—no problem at all?

Alimentary pharmacology & therapeutics, 2018-06, Vol.47 (11), p.1552-1553

2018

Volltextzugriff (PDF)

Percutaneous Transsplenic Balloon-Assisted Transjugular Intrahepatic Portosystemic Shunt Placement in Patients with Portal Vein Obliteration for Portal Vein Recanalization: Feasibility, Safety and Effectiveness

Cardiovascular and interventional radiology, 2022-05, Vol.45 (5), p.696-702

2022

Volltextzugriff (PDF)

Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients

Clinical microbiology and infection, 2015-07, Vol.21 (7), p.710.e1-710.e9

2015

Volltextzugriff (PDF)

Predictors of nosocomial spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis and ascites

Journal of hepatology, 2017, Vol.66 (1), p.S578-S579

2017

Volltextzugriff (PDF)

Proton pump inhibitors are associated with a higher risk for spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites

Journal of hepatology, 2017, Vol.66 (1), p.S578-S578

2017

Volltextzugriff (PDF)

Commentary: detection of low level viraemia in telaprevir‐based triple therapy for hepatitis C virus – authors' reply

Alimentary pharmacology & therapeutics, 2014-03, Vol.39 (5), p.544-545

2014

Volltextzugriff (PDF)

Treatment strategies for acute-on-chronic liver failure

Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2021-02, Vol.116 (1), p.3

2021

Volltextzugriff (PDF)

Letter: telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis

Alimentary pharmacology & therapeutics, 2014-06, Vol.39 (11), p.1342-1344

2014

Volltextzugriff (PDF)

Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir

Alimentary pharmacology & therapeutics, 2014-01, Vol.39 (1), p.85-92

2014

Volltextzugriff (PDF)

The clinical significance of drug–drug interactions in the era of direct‐acting anti‐viral agents against chronic hepatitis C

Alimentary pharmacology & therapeutics, 2013-12, Vol.38 (11-12), p.1365-1372

2013

Volltextzugriff (PDF)

Clinical Utility of Hepatitis B Core-Related Antigen (HBcrAg) in the Treatment of Hepatitis Delta

Journal of hepatology, 2016, Vol.64 (2), p.S586-S586

2016

Volltextzugriff (PDF)

Use of the 6 million viral load cut-off to guide treatment duration with ledipasvir/sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection: results from the German Hepatitis C-Registry (DHC-R)

Journal of hepatology, 2017, Vol.66 (1), p.S519-S520

2017

Volltextzugriff (PDF)

Can HCV core antigen replace HCV RNA testing in the era of direct-acting antivirals?

Journal of hepatology, 2017, Vol.66 (1), p.S496-S496

2017

Volltextzugriff (PDF)

P0735 : Assessment of baseline viral load cut-off for shortened ledipasvir/sofosbuvir therapy by widely used HCVRNA assays

Journal of hepatology, 2015-04, Vol.62, p.S600-S600

2015

Volltextzugriff (PDF)

P0754 : Clinical significance of drug-drug interactions during therapy with novel daas against HCV

Journal of hepatology, 2015-04, Vol.62, p.S612-S612

2015

Volltextzugriff (PDF)

P667 HEPATITIS B CORE-RELATED ANTIGEN (HBcrAg) LEVELS IN THE NATURAL HISTORY OF HEPATITIS B INFECTION IN A LARGE EUROPEAN COHORT

Journal of hepatology, 2014-04, Vol.60 (1), p.S291-S291

2014

Volltextzugriff (PDF)

P0877 : HCVRNA levels assessed at early stages of sofosbuvir/ribavirin dual therapy identify relapse patients

Journal of hepatology, 2015-04, Vol.62, p.S670-S670

2015

Volltextzugriff (PDF)

P0667 : Interruption of nucleos(t)ide analogue therapy for HBeAg-negative chronic hepatitis B – A new concept to achieve HBsAg decline?

Journal of hepatology, 2015-04, Vol.62, p.S571-S572

2015

Volltextzugriff (PDF)

P0767 : Clinical utility of hepatitis C virus core antigen testing in the monitoring of treatment naïve non-cirrhotic patients receiving an all-oral, interferon-free regimien

Journal of hepatology, 2015-04, Vol.62, p.S617-S617

2015

Volltextzugriff (PDF)

Behandlungsstrategien des akut-auf-chronischen Leberversagens

Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2021-02, Vol.116 (1), p.3-16

2021

Volltextzugriff (PDF)

855 A CLINICAL TRIAL EVALUATING LOW HCVRNA VIREMIA IN PATIENTS TREATED WITH TRIPLE THERAPY REGIMENS: IMPLICATIONS FOR PATIENT MANAGEMENT USING DIFFERENT ASSAYS IN CLINICAL PRACTICE

Journal of hepatology, 2013-04, Vol.58, p.S350-S351

2013

Volltextzugriff (PDF)

856 CLINICAL SIGNIFICANCE OF DRUG–DRUG-INTERACTIONS IN THE ERA OF DIRECT ACTING ANTIVIRAL AGENTS AGAINST HEPATITIS C – A REAL-WORLD EXPERIENCE

Journal of hepatology, 2013-04, Vol.58, p.S351-S351

2013

Volltextzugriff (PDF)

HBsAg decline after interrupting nucleos(t)ide analogue therapy in HVeAg-negative chronic hepatitis B

Journal of clinical virology, 2015-08, Vol.69, p.233-233

2015

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(59)
Tagungsberichte
(14)

Sprache

Englisch
(63)
Deutsch
(18)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D

Alkalosis, albumin, ammonia and hepatic encephalopathy

Editorial: retreatment of DAA‐failures—no problem at all?

Percutaneous Transsplenic Balloon-Assisted Transjugular Intrahepatic Portosystemic Shunt Placement in Patients with Portal Vein Obliteration for Portal Vein Recanalization: Feasibility, Safety and Effectiveness

Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients

Predictors of nosocomial spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis and ascites

Proton pump inhibitors are associated with a higher risk for spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites

Commentary: detection of low level viraemia in telaprevir‐based triple therapy for hepatitis C virus – authors' reply

Treatment strategies for acute-on-chronic liver failure

Letter: telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis

Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir

The clinical significance of drug–drug interactions in the era of direct‐acting anti‐viral agents against chronic hepatitis C

Clinical Utility of Hepatitis B Core-Related Antigen (HBcrAg) in the Treatment of Hepatitis Delta

Use of the 6 million viral load cut-off to guide treatment duration with ledipasvir/sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection: results from the German Hepatitis C-Registry (DHC-R)

Can HCV core antigen replace HCV RNA testing in the era of direct-acting antivirals?

P0735 : Assessment of baseline viral load cut-off for shortened ledipasvir/sofosbuvir therapy by widely used HCVRNA assays

P0754 : Clinical significance of drug-drug interactions during therapy with novel daas against HCV

P667 HEPATITIS B CORE-RELATED ANTIGEN (HBcrAg) LEVELS IN THE NATURAL HISTORY OF HEPATITIS B INFECTION IN A LARGE EUROPEAN COHORT

P0877 : HCVRNA levels assessed at early stages of sofosbuvir/ribavirin dual therapy identify relapse patients

P0667 : Interruption of nucleos(t)ide analogue therapy for HBeAg-negative chronic hepatitis B – A new concept to achieve HBsAg decline?

P0767 : Clinical utility of hepatitis C virus core antigen testing in the monitoring of treatment naïve non-cirrhotic patients receiving an all-oral, interferon-free regimien

Behandlungsstrategien des akut-auf-chronischen Leberversagens

855 A CLINICAL TRIAL EVALUATING LOW HCVRNA VIREMIA IN PATIENTS TREATED WITH TRIPLE THERAPY REGIMENS: IMPLICATIONS FOR PATIENT MANAGEMENT USING DIFFERENT ASSAYS IN CLINICAL PRACTICE

856 CLINICAL SIGNIFICANCE OF DRUG–DRUG-INTERACTIONS IN THE ERA OF DIRECT ACTING ANTIVIRAL AGENTS AGAINST HEPATITIS C – A REAL-WORLD EXPERIENCE

HBsAg decline after interrupting nucleos(t)ide analogue therapy in HVeAg-negative chronic hepatitis B

Suchergebnisse filtern